Zimmer Biomet Holdings, Inc. has entered into a new financing agreement as of June 27, 2025. The company has secured a five-year revolving credit facility valued at $1.5 billion through an agreement with JPMorgan Chase Bank, N.A., acting as the administrative agent, along with other lenders. This Five-Year Revolving Credit Agreement, which is unsecured, includes options for two one-year extensions, subject to lender consent. Additionally, Zimmer Biomet has the ability to request an increase of the facility by up to $500 million. The funds will be utilized for general corporate purposes, with interest rates set at floating rates based on either an adjusted Term SOFR or an alternate base rate, plus an applicable margin. This new agreement replaces a previous five-year credit arrangement, which was terminated upon entering the new agreement.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。